Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From InterMune, Inc.
The company is on track to file an sNDA for lumateperone after a Phase III clinical trial met the primary endpoint in bipolar I and II disorder.
The latest breakthrough therapy designation announcements from the Pink Sheet’s US FDA Performance Tracker
NICE says that Bavencio plus Inlyta will be made available via the Cancer Drugs Fund for advanced kidney cancer while more evidence is collected to support the combination therapy's routine use on the National Health Service.